<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423696</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000523435</org_study_id>
    <secondary_id>FRE-FNCLCC-ACCORD-13-0503</secondary_id>
    <secondary_id>EU-20666</secondary_id>
    <secondary_id>2005-000070-43</secondary_id>
    <nct_id>NCT00423696</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>Phase II Randomized Study of First-Line Therapy Comprising Bevacizumab and Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil (FOLFIRI) Versus Bevacizumab and Irinotecan Hydrochloride and Capecitabine (XELIRI) in Patients With Unresectable Metastatic Colorectal Cancer [ACCORD]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the&#xD;
      growth of colorectal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving bevacizumab together with combination chemotherapy may&#xD;
      kill more tumor cells. It is not yet known which combination chemotherapy regimen is more&#xD;
      effective when given together with bevacizumab in treating patients with colorectal cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying bevacizumab to compare how well it works&#xD;
      when given together with two different combination chemotherapy regimens as first-line&#xD;
      therapy in treating patients with metastatic colorectal cancer that cannot be removed by&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the progression-free survival at 6 months in patients with unresectable&#xD;
           metastatic colorectal cancer treated with first-line therapy comprising bevacizumab and&#xD;
           irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) vs bevacizumab&#xD;
           and irinotecan hydrochloride and capecitabine (XELIRI).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the toxicities of these regimens in these patients.&#xD;
&#xD;
        -  Compare the objective response rate and duration of response in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Compare the tumor control in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the progression-free and overall survival of patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is an open-label, randomized, multicenter study. Patients are stratified&#xD;
      according to participating center, WHO performance status (0 or 1 vs 2), age (&lt; 65 years vs ≥&#xD;
      65 years), and number of metastatic sites (1 vs ≥ 2). Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive bevacizumab IV over 30-90 minutes, irinotecan hydrochloride IV&#xD;
           over 90 minutes, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV&#xD;
           continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for 12&#xD;
           courses in the absence of disease progression or unacceptable toxicity. Patients may&#xD;
           then continue to receive bevacizumab alone every 2 weeks in the absence of disease&#xD;
           progression.&#xD;
&#xD;
        -  Arm II: Patients receive bevacizumab IV over 30-90 minutes and irinotecan hydrochloride&#xD;
           IV over 90 minutes on day 1 and oral capecitabine on days 1-14. Treatment repeats every&#xD;
           3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.&#xD;
           Patients may then continue to receive bevacizumab alone every 3 weeks in the absence of&#xD;
           disease progression.&#xD;
&#xD;
      Quality of life is assessed periodically.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 144 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2006</start_date>
  <completion_date type="Actual">August 1, 2011</completion_date>
  <primary_completion_date type="Actual">July 28, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 6 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of objective responses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of stable disease responses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response and stable disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>bevacizumab + FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bevacizumab + XELIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>bevacizumab + FOLFIRI</arm_group_label>
    <arm_group_label>bevacizumab + XELIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>bevacizumab + XELIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>bevacizumab + FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>bevacizumab + FOLFIRI</arm_group_label>
    <arm_group_label>bevacizumab + XELIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>bevacizumab + FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed colorectal cancer&#xD;
&#xD;
               -  Unresectable metastatic disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm³&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL (transfusion allowed)&#xD;
&#xD;
          -  INR &lt; 1.5&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Creatinine clearance &gt; 30 mL/min&#xD;
&#xD;
          -  Urine protein &lt; 2+ OR ≤ 1 g/L by 24-hour urine collection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No contraindications to study therapy&#xD;
&#xD;
          -  No gastrointestinal or duodenal ulcers&#xD;
&#xD;
          -  No AIDS&#xD;
&#xD;
          -  No serious illness, active infection, or other serious condition that would preclude&#xD;
             study therapy&#xD;
&#xD;
          -  No coagulation problem&#xD;
&#xD;
          -  No bleeding diathesis&#xD;
&#xD;
          -  No sensitivity to Chinese hamster ovarian cells or other recombinant human antibodies&#xD;
&#xD;
          -  No severe renal insufficiency&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No active or severe cardiovascular conditions, including the following:&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  New York Heart Association class II-IV cardiac insufficiency&#xD;
&#xD;
               -  Severe cardiac arrhythmia (even if treated)&#xD;
&#xD;
          -  No primitive stenosis or symptomatic peritoneal carcinosis causing a risk of&#xD;
             intestinal subocclusion or occlusion&#xD;
&#xD;
          -  No nonhealing wound or fracture&#xD;
&#xD;
          -  No prior thromboembolic disease&#xD;
&#xD;
          -  No other cancer within the past 2 years except for basal cell skin cancer or carcinoma&#xD;
             in situ of the uterine cervix&#xD;
&#xD;
          -  No geographical, social, or psychological condition that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  At least 6 months since prior adjuvant chemotherapy (fluorouracil with or without&#xD;
             oxaliplatin)&#xD;
&#xD;
               -  No prior adjuvant chemotherapy comprising irinotecan hydrochloride with or&#xD;
                  without bevacizumab&#xD;
&#xD;
          -  At least 28 days since prior major surgery&#xD;
&#xD;
          -  Prior radiotherapy allowed except to target lesions&#xD;
&#xD;
          -  At least 10 days since prior anticoagulants&#xD;
&#xD;
          -  No concurrent chronic acetylsalicylic acid (at doses &gt; 325 mg/day)&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Ducreux, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>C.H.U. de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique des Quatre Pavillons</name>
      <address>
        <city>Lormont</city>
        <zip>33310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Francheville</name>
      <address>
        <city>Perigueux</city>
        <zip>24004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35062</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Malka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, Pierga JY, Conroy T, Chauffert B, François E, Guichard P, Galais MP, Cvitkovic F, Ducreux M, Farace F. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol. 2012 Apr;23(4):919-27. doi: 10.1093/annonc/mdr365. Epub 2011 Aug 8.</citation>
    <PMID>21825101</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

